Kim, Jeong Hee
Choi, Jeong In
Che, Young Hyun
Sung, Su Haeng
Lee, Hojae
Lee, Sun
Park, Jae-Hoon
Lee, Yun-Il
Lee, Young-Sam
Jeon, Won Bae
Kim, Yong Jun http://orcid.org/0000-0002-5374-712X
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2022M3A9H1016308, NRF-2022R1F1A1066611, NRF-2019M3A9H1103478)
Korean Fund for Regenerative Medicine (2021M3E5E5096744)
Article History
Received: 9 February 2023
Revised: 15 June 2023
Accepted: 3 July 2023
First Online: 23 August 2023
Declarations
:
: Won Bae Jeon is the founder and CEO of Excellamol Inc., and has employment and financial relationships with Excellamol Inc., including patent inventions. All other authors have no financial conflicts of interests.
: All experiments using hESCs were conducted in accordance with the regulation KHSIRB-20–489 permitted by Kyung Hee University IRB.